A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States

Journal of Medical Economics

Volumn 15, Issue 4, 2012, Pages 766-775

  Pollock, Richard F ^a   Curtis, Bradley H ^b   Valentine, William J ^a  

^a Ossian Health Economics and Communications   (Switzerland)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Biphasic insulin; Cost effectiveness; Long acting analog insulin; United States

Indexed keywords

INSULIN GLARGINE; INSULIN LISPRO;

ARTICLE; COHORT ANALYSIS; COMPUTER MODEL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; META ANALYSIS; META ANALYSIS (TOPIC); QUALITY OF LIFE; SENSITIVITY ANALYSIS; UNITED STATES;

COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH EXPENDITURES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN LISPRO; LIFE EXPECTANCY; LONG-TERM CARE; MALE; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 84862513654     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.675890     Document Type: Article

References (34)

1. Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:293-301
2. American Diabetes Association. Economic costs of diabetes in the U.S. In 2007. Diabetes Care 2008;31:596-615
3. U.K. Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58
4. Sarpong E, Miller E. Agency for Healthcare Research and Quality Statistical Brief #293: trends in the pharmaceutical treatment of diabetes: a comparison of utilization and expenditures, 1997 to 2007. 2010. http://www.meps. ahrq.gov/mepsweb/data-files/publications/st293/stat293.shtml. Accessed March 9, 2012
5. Bonafede MM, Kalsekar A, Pawaskar M, et al. A retrospective database analysis of insulin use patterns in insulin-na?̈ve patients with type 2 diabetes initiating basal insulin or mixtures. Patient Prefer Adherence 2010;4:147-56
6. Valentine WJ, Palmer AJ, Erny-Albrecht KM, et al. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH. Adv Ther 2006;23:191-207 (Pubitemid 43876664)
7. Pscherer S, Dietrich ES, Dippel FW, et al. Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany. Int J Clin Pharmacol Ther 2010;48:129-37
8. Guillermin AL, Samyshkin Y, Wright D, et al. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis. J Med Econ 2011;14:207-16
9. Tunis SL, Minshall ME, Conner C, et al. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis. Curr Med Res Opin 2009;25:1273-84
10. Brä ndle M, Azoulay M, Greiner RA. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther 2007;45: 203-20 (Pubitemid 46629383)
11. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(1 Suppl):S5-26
12. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004; 20(1 Suppl):S27-40 (Pubitemid 39349906)
13. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
14. Tunis SL, Minshall ME. Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the United States. Am J Manag Care 2008;14: 131-40 (Pubitemid 351367356)
15. Jones S, Benroubi M, Castell C, et al. Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study. Curr Med Res Opin 2009;25:691-700
16. Centers for Disease Control and Prevention. Cigarette smoking among adults-United States, 2004. JAMA 2006;295:749-51
17. National Institute on Alcohol Abuse and Alcoholism (NIAAA). NIAAA 2006 http://www.niaaa.nih.gov/Resources/GraphicsGallery/consfigs4text. htm. Accessed March 9, 2012
18. National Diabetes Data Group; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes in America. 2nd ed. NIH Publication No. 95-1468, 1995
19. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N (Pubitemid 28507114)
20. Phillips SJ, Whisnant JP, O'Fallon WM, et al. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clin Proc 1990;65:344-59 (Pubitemid 20124303)
21. Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000;23:754-8 (Pubitemid 30414188)
22. Brandle M, Zhou H, Smith BR, et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26:2300-4 (Pubitemid 36993316)
23. Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med 1992;152:610-6
24. Qayyum R, Bolen S, Maruthur N, et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med 2008;149:549-59
25. O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003;25:1017-38 (Pubitemid 36459706)
26. Pelletier EM, Smith PJ, Boye KS, et al. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research. Appl Health Econ Health Policy 2008;6:103-12
27. World Health Organization Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical/Defined Daily Dose Index 2010. http://www.whocc.no/atc-ddd-index/?codeA10AE. Accessed May 11, 2010
28. Gold MR, Siegel JE, Russell LB, et al., eds. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press, 1996
29. Levy AR, Christensen TL, Johnson JA. Utility values for symptomatic nonsevere hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health Qual Life Outcomes 2008;29:73
30. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002; 22:340-9 (Pubitemid 34791321)
31. Coffey JT, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002;25:2238-43 (Pubitemid 41071034)
32. Ilag LL, Kerr L, Malone JK, et al. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther 2007;29:1254-70 (Pubitemid 351172223)
33. Lasserson DS, Glasziou P, Perera R, et al. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 2009; 52:1990-2000
34. Karter AJ, Parker MM, Moffet HH, et al. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care 2006; 29(8):1757-63 (Pubitemid 44156626)